Tumor Cell Nanovaccines Based on Genetically Engineered Antibody-Anchored Membrane

Tumor Cell Nanovaccines Based on Genetically Engineered Antibody-Anchored Membrane

© 2023 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 35(2023), 13 vom: 30. März, Seite e2208923
1. Verfasser: Li, Yuanke (VerfasserIn)
Weitere Verfasser: Zhang, Haoqi, Wang, Ruikun, Wang, Yuan, Li, Ruonan, Zhu, Mingsheng, Zhang, Xiangyun, Zhao, Zhen, Wan, Yajuan, Zhuang, Jie, Zhang, Hongkai, Huang, Xinglu
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article agonistic antibodies cell membranes immunotherapy nanovaccines tumor Antibodies CD40 Antigens
Beschreibung
Zusammenfassung:© 2023 Wiley-VCH GmbH.
Despite the promise in whole-tumor cell vaccines, a key challenge is to overcome the lack of costimulatory signals. Here, agonistic-antibody-boosted tumor cell nanovaccines are reported by genetically engineered antibody-anchored membrane (AAM) technology, capable of effectively activating costimulatory pathways. Specifically, the AAM can be stably constructed following genetic engineering of tumor cell membranes with anti-CD40 single chain variable fragment (scFv), an agonistic antibody to induce costimulatory signals. The nanovaccines are versatilely designed and obtained based on the anti-CD40 scFv-anchored membrane and nanotechnology. Following vaccination, the anti-CD40 scFv-anchored membrane nanovaccine (Nano-AAM/CD40) significantly facilitates dendritic cell maturation in CD40-humanized transgenic mice and subsequent adaptive immune responses. Compared to membrane-based nanovaccines alone, the enhanced antitumor efficacy in both "hot" and "cold" tumor models of the Nano-AAM/CD40 demonstrates the importance of agonistic antibodies in development of tumor-cell-based vaccines. To expand the design of nanovaccines, further incorporation of cell lysates into the Nano-AAM/CD40 to conceptually construct tumor cell-like nanovaccines results in boosted immune responses and improved antitumor efficacy against malignant tumors inoculated into CD40-humanized transgenic mice. Overall, this genetically engineered AAM technology provides a versatile design of nanovaccines by incorporation of tumor-cell-based components and agonistic antibodies of costimulatory immune checkpoints
Beschreibung:Date Completed 30.03.2023
Date Revised 30.03.2023
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202208923